Article Details
Retrieved on: 2024-06-21 22:17:52
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Neurona Therapeutics' NRTX-1001, a regenerative cell therapy for drug-resistant mesial temporal lobe epilepsy, which has received FDA's RMAT designation. This showcases the intersection of regenerative medicine, epilepsy treatment, and pharmaceuticals policy.
Article found on: www.cgtlive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here